Investment Thesis
Allogene is a pre-commercial stage biopharmaceutical company with zero revenue and severe cash burn of $149.2M annually, indicating it is not yet generating product sales. While the company maintains a strong liquidity position with a 7.93x current ratio and $51.7M in cash, at the current burn rate this runway extends only to mid-2026, creating significant going concern risk without successful clinical advancement or financing.
ALLO Strengths
- Excellent liquidity position with 7.93x current ratio and $51.7M cash on hand
- No long-term debt obligations reducing financial leverage risk
- Reasonable balance sheet with total assets of $415.9M and modest liabilities of $123.4M
- Positive EPS trend with 34.1% YoY improvement despite continued losses
ALLO Risks
- Zero revenue generation with 100% YoY decline indicates no commercial products yet approved
- Massive operating cash burn of $149.2M annually with only ~4 months of cash runway remaining
- Negative net income of -$190.9M and negative ROE of -65.3%, ROA of -45.9% showing significant shareholder value destruction
- High risk of dilutive financing or failed clinical trials given current burn rate and pre-commercial status
- 12 Form 4 insider filings in last 90 days warrant investigation for potential negative signals
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway projections
- Clinical trial progress and regulatory milestone announcements for lead programs
- Timing and results of any financing activities or capital raises
- Product revenue recognition timeline if any programs achieve approval
ALLO Financial Metrics
ALLO Profitability Ratios
ALLO Balance Sheet & Liquidity
ALLO 5-Year Financial Trend
5-Year Trend Summary: Allogene Therapeutics, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
ALLO Growth Metrics (YoY)
ALLO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$41.4M | $-0.19 |
| Q2 2025 | N/A | -$50.9M | $-0.23 |
| Q1 2025 | N/A | -$59.7M | $-0.28 |
| Q3 2024 | N/A | -$62.3M | $-0.32 |
| Q2 2024 | N/A | -$65.0M | $-0.35 |
| Q1 2024 | $22.0K | -$65.0M | $-0.38 |
| Q3 2023 | $43.0K | -$61.3M | $-0.37 |
| Q2 2023 | $44.0K | -$74.8M | $-0.52 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ALLO Capital Allocation
ALLO SEC Filings
Access official SEC EDGAR filings for Allogene Therapeutics, Inc. (CIK: 0001737287)